HoldsUp

Georgia Ede

Dr. Georgia Ede works in the field of metabolic psychiatry. Her published research focuses on the application of ketogenic metabolic therapy and ketogenic diets for treating mental health disorders and refractory mental illness. Her work also examines the use of ketogenic diets for weight management, alongside the contraindications, side effects, and clinical best practices associated with these dietary interventions.

18 claims checked on air: 2 context 1 contradicted 5 overstated 8 supported 2 unverified

What they said on air

2 citing their own research

0:00:00supportedvery lowtheir own paperRevolutionizing Mental Health: The Rise of Metabolic Psychia

In a published study of 31 psychiatric inpatients, 28 were able to stay on a ketogenic diet for 2 weeks or longer, all 28 improved substantially, 43% achieved full clinical remission from their primary psychiatric diagnosis, and 64% were discharged on reduced psychiatric medication.

"28 of those 31 patients were able to stay on the diet for 2 weeks or longer, which is what you need to do to start to see benefits. All 28 of those patients improved substantially to the point that 43% of them achieved full clinical remission from their primary psychiatric diagnosis and 64% of them left the hospital on less psychiatric medication" (said at 0:00:00)

The speaker accurately describes the published findings of a 2022 retrospective analysis (Danan et al., 2022, co-authored by Georgia Ede) evaluating 31 psychiatric inpatients placed on an adjunctive ketogenic diet. In that study, 28 of 31 patients adhered to the diet for more than 14 days, 100% (28/28) demonstrated clinical improvement, 43% (12/28) achieved clinical remission (defined by clinical rating scales or Clinical Global Impression scores), and 64% (18/28) were discharged on reduced psychiatric medication. Because this study is an uncontrolled, retrospective chart review, the certainty of evidence for the therapeutic efficacy of the ketogenic diet in this population is very low.

0:14:05unverifiedvery lowRevolutionizing Mental Health: The Rise of Metabolic Psychia

Matt Baszucki suffered from severe bipolar disorder with psychotic features, failed 29 medications, and achieved sustained remission after starting a ketogenic diet under Dr. Chris Palmer.

"Matt Baszucki was suffering with severe bipolar disorder with psychotic features, was on the brink of homelessness, had had his college studies interrupted, and had tried 29 different medications, had been in and out of the hospital. And it wasn't until he met with Dr. Chris Palmer and started a ketogenic diet that he was able to set himself on the path to now complete, sustained remission" (said at 0:14:05)

No published record matching the specific case of Matt Baszucki's treatment history and remission on a ketogenic diet under Dr. Chris Palmer was located; this does not prove the claim false.

0:17:29supportedhighRevolutionizing Mental Health: The Rise of Metabolic Psychia

The scientific hypothesis that depression is caused by deficient serotonin activity in the brain has largely been debunked.

"the science behind the serotonin hypothesis is extraordinarily thin to nonexistent. That serotonin—the idea that the reason why people develop depression is because they don't have enough serotonin activity in the brain—has largely been debunked." (said at 0:17:29)

A landmark systematic umbrella review evaluated the primary research areas examining the serotonin hypothesis of depression (including studies of serotonin and 5-HIAA metabolite levels, 5-HT1A receptor binding, SERT levels, tryptophan depletion, and SERT gene/gene-environment interactions). The review concluded that across all major research domains, there is no consistent evidence of an association between serotonin activity or concentration and depression, and no empirical support for the hypothesis that depression is caused by deficient serotonin activity.

0:21:04overstatedlowRevolutionizing Mental Health: The Rise of Metabolic Psychia

High levels of refined carbohydrates and vegetable oils alter the kynurenine pathway through inflammation and oxidative stress, impacting neurotransmitters including serotonin, melatonin, dopamine, glutamate, and GABA.

"there is this key pathway, this key regulatory pathway in the brain, it's called the kynurenine pathway. And basically this pathway helps regulate the production and activity of a number of different neurotransmitters in the brain, a number of different chemicals, many of which are also the targets of the psychiatric medicines that we prescribe. So serotonin, melatonin, dopamine, glutamate, GABA—many different neurotransmitters are affected by this pathway. But this pathway can be thrown far out of balance by these refined carbohydrates and vegetable oils, because the refined carbohydrates and vegetable oils cause inflammation and something called oxidative stress" (said at 0:21:04)

The biological mechanisms described by the speaker are partially grounded in psychoneuroimmunology: inflammatory cytokines and oxidative stress can activate enzymes such as indoleamine 2,3-dioxygenase (IDO), shifting tryptophan metabolism away from serotonin and melatonin synthesis and down the kynurenine pathway, yielding neuroactive metabolites that interact with glutamatergic and other neurotransmitter systems. However, attributing specific, pronounced dysregulation of the kynurenine pathway directly to refined carbohydrates and vegetable oils in humans overstates the current clinical evidence. Narrative and systematic reviews in nutritional psychiatry note that while broad dietary patterns plausibly modulate inflammation, oxidative stress, and tryptophan-kynurenine metabolism, the body of evidence connecting specific dietary elements like refined carbohydrates or vegetable oils to these pathway shifts consists primarily of theoretical models and preclinical animal studies.

0:26:43overstatedlowRevolutionizing Mental Health: The Rise of Metabolic Psychia

Under the influence of neuroinflammation, glutamate levels can spike up to one hundred times baseline, causing excitotoxicity that damages the blood-brain barrier, hippocampus, and mitochondrial membranes.

"and you have steep spikes in glutamate, this neurotransmitter called glutamate, up to a hundred times its previous baseline. And then you can develop something called glutamate excitotoxicity. So glutamate is the brain's gas pedal; it's the brain's primary excitatory neurotransmitter. And so when you've got high levels of glutamate—this is all just coming from inflammation and oxidative stress from eating the wrong way—when you get these big surges in glutamate, glutamate is directly physically damaging to all critical structures of the brain, including the blood-brain barrier, including the hippocampus, the brain's learning and memory center, including the delicate membranes of the mitochondria" (said at 0:26:43)

The mechanistic components of the claim are well-documented in preclinical and neurotrauma models: elevated extracellular glutamate causes excitotoxicity through calcium overload, leading to mitochondrial membrane disruption, hippocampal neuronal injury, and blood-brain barrier dysfunction, and this interacts bidirectionally with neuroinflammation. However, framing this as a 100-fold surge in baseline glutamate driven primarily by diet-induced systemic inflammation is an overstatement. Massive multi-fold extracellular glutamate spikes are typically documented in acute, catastrophic insults such as status epilepticus, severe traumatic brain injury, or cerebral ischemia rather than ordinary dietary inflammation.

0:30:26needs contextmoderateRevolutionizing Mental Health: The Rise of Metabolic Psychia

All cells inside the brain possess both glucose receptors and insulin receptors.

"And all of the cells inside the brain not only have glucose receptors, but they also have insulin receptors." (said at 0:30:26)

The speaker's premise that brain cells broadly express machinery for both glucose uptake and insulin signaling is well established across major brain cell types. Neurons, astrocytes, oligodendrocytes, microglia, and cerebral endothelial cells widely express insulin receptors alongside glucose transporters (such as GLUT1, GLUT3, and insulin-sensitive GLUT4). However, two technical clarifications are necessary: first, glucose is taken up across cellular membranes primarily via glucose transporters (GLUT proteins) rather than classical ligand receptors; second, the density and expression of insulin receptors and specific GLUT isoforms vary considerably across specific cell subtypes and brain regions rather than being uniformly present on literally every individual cell.

0:30:26supportedmoderateRevolutionizing Mental Health: The Rise of Metabolic Psychia

The vast majority of Americans currently have at least some degree of insulin resistance.

"now the vast majority of Americans have at least now some degree of insulin resistance" (said at 0:30:26)

Nationally representative epidemiological data from the National Health and Nutrition Examination Survey (NHANES) support the claim. An analysis of NHANES 2009–2016 data (Araújo et al., 2019, PMID: 30484738) found that only 12.2% of US adults met all criteria for optimal cardiometabolic health (which includes normal glucose, blood pressure, lipid profiles, and waist circumference without medication), meaning approximately 88% of American adults have at least one cardiometabolic abnormality linked to insulin resistance. Furthermore, when evaluating insulin resistance and dysglycemia broadly (including metabolic syndrome, prediabetes, and type 2 diabetes), the majority of American adults exhibit markers of impaired metabolic health.

0:30:45supportedmoderateRevolutionizing Mental Health: The Rise of Metabolic Psychia

When the brain develops insulin resistance, insulin has a harder time crossing into the brain.

"if the brain becomes insulin resistant, then insulin has a harder and harder time crossing into the brain." (said at 0:30:45)

Circulating insulin crosses the blood-brain barrier (BBB) via a saturable, receptor-mediated transport mechanism. In preclinical and clinical models of obesity, type 2 diabetes, and central nervous system (CNS) insulin resistance (frequently observed in Alzheimer's disease), insulin transport across the BBB is significantly reduced and impaired. Central insulin signaling and insulin receptor function have also been shown to directly regulate the rate of BBB insulin influx, confirming that insulin resistance in the CNS and BBB endothelial cells diminishes the brain's uptake of peripheral insulin.

0:31:12overstatedmoderateRevolutionizing Mental Health: The Rise of Metabolic Psychia

By the time subtle signs of memory problems are noticed, the brain can already have lost up to 25% of its glucose processing capacity.

"And so by the time you notice any signs, even subtle signs of memory problems, the brain can already have lost up to 25% of its glucose processing capacity." (said at 0:31:12)

FDG-PET neuroimaging demonstrates that cerebral glucose hypometabolism begins presymptomatically and is present in mild cognitive impairment (MCI) and early Alzheimer's disease. However, quantitative PET studies indicate that at the earliest stages of subtle cognitive impairment (MCI), glucose metabolism is reduced by roughly 7% to 15% in specific vulnerable brain regions (such as the cingulate and temporoparietal cortex), rather than an overall 25% loss across the entire brain. Regional reductions approaching or exceeding 20% to 25% are typically observed in established early-to-moderate Alzheimer's dementia rather than at the very first subtle emergence of memory symptoms.

0:40:39supportedmoderateRevolutionizing Mental Health: The Rise of Metabolic Psychia

Experiments by Stephen Cunnane and others show that when brain cells are given both glucose and ketones, they choose to burn a mixture of the two.

"experiments by Dr. Cunnane and others have shown this: that if you take a brain cell and you give it all the glucose it could ever want, but you also give it ketones, it will choose to burn a mixture of the two" (said at 0:40:39)

Dual-tracer positron emission tomography (PET) research led by Stephen Cunnane and colleagues in healthy humans and clinical populations demonstrates that the brain utilizes both glucose and ketone bodies simultaneously when ketones are available. In clinical PET studies measuring cerebral metabolic rates with 11C-acetoacetate and 18F-fluorodeoxyglucose, brain ketone uptake increases in direct proportion to circulating plasma ketone levels, operating alongside ongoing glucose metabolism and providing a dual-fuel energy mixture rather than relying exclusively on a single fuel source.

0:40:54needs contextlowRevolutionizing Mental Health: The Rise of Metabolic Psychia

Ketones burn with less inflammation and less oxidative stress compared to glucose.

"One is that ketones burn more cleanly and more efficiently and more safely than glucose does, with a lot less inflammation, a lot less oxidative stress." (said at 0:40:54)

The assertion that ketone bodies act as a cleaner fuel that reduces oxidative stress and inflammation relative to glucose is broadly aligned with current bioenergetic models, but it requires mechanistic qualification. Review literature demonstrates that induced ketosis lowers overall cellular oxidative stress and suppresses inflammatory signaling pathways. However, detailed metabolic reviews indicate that ketone oxidation does not simply bypass reactive oxygen species (ROS) production entirely; rather, ketolysis acutely generates a mild transient mitochondrial ROS signal that triggers an adaptive (hormetic) response—upregulating protective pathways such as Nrf2, sirtuins, and endogenous antioxidant enzymes. Thus, while the downstream result of ketone utilization is reduced net oxidative and inflammatory stress, the mechanism involves an active adaptive cellular response rather than passive clean burning. Furthermore, much of the mechanistic evidence is derived from preclinical and cellular studies.

0:41:20contradictedlowRevolutionizing Mental Health: The Rise of Metabolic Psychia

Certain biological pathways in the brain cannot utilize ketones and can only use glucose because ketone molecules are too small.

"there are certain pathways in the brain that can't use ketones, they can only use glucose because ketones are too small." (said at 0:41:20)

While certain biological pathways in the brain (such as the pentose phosphate pathway) require glucose rather than ketone bodies to provide specific metabolites like NADPH and ribose-5-phosphate, this functional requirement is not because ketone bodies are "too small." Ketone bodies (beta-hydroxybutyrate, 104 Da; acetoacetate, 102 Da) are smaller molecules than glucose (180 Da), but substrate specificity in metabolic pathways is governed by enzymatic binding site structure and chemical properties, not molecular size. PMID 14769485 notes that glucose is required for specific pathways like the pentose phosphate pathway that cannot be fulfilled by ketones, but this is due to chemical structure and pathway stoichiometry rather than molecular size.

0:44:52supportedvery lowtheir own paperRevolutionizing Mental Health: The Rise of Metabolic Psychia

In a 2022 published study by Dr. Albert Danan and co-authors on 31 treatment-resistant psychiatric inpatients, 28 stayed on a ketogenic diet for 2 weeks or longer, 43% achieved full clinical remission, and 64% were discharged on less psychiatric medication.

"So this study, which I was a co-author on—this study was published in 2022. The clinical work was done by my friend and colleague Dr. Albert Danan, who is a psychiatrist who's been practicing psychiatry in Toulouse, France for more than 35 years now. And he invited 31 of his most treatment-resistant patients with major depression, bipolar disorder, and schizophrenia to come into the hospital and try a mildly ketogenic whole-foods diet under his supervision to see whether or not it would be helpful... 28 of those 31 patients were able to stay on the diet for two weeks or longer... 43% of them achieved full clinical remission from their primary psychiatric diagnosis and 64% of them left the hospital on less psychiatric medication." (said at 0:44:52)

The speaker accurately describes the findings of the 2022 retrospective study by Danan et al. (co-authored by Georgia Ede), published in Frontiers in Psychiatry. In that analysis of 31 hospitalized adults with treatment-resistant major depression, bipolar disorder, or schizoaffective disorder, 28 patients adhered to a carbohydrate-restricted ketogenic diet for at least 14 days. Among those 28 patients, 43% (12/28) achieved clinical remission (defined by clinical rating scales) and 64% (18/28) were discharged on reduced psychiatric medication dosages. Because this was an uncontrolled, retrospective chart review of clinical care rather than a randomized controlled trial, the certainty of evidence for clinical efficacy is very low.

0:50:37overstatedmoderateRevolutionizing Mental Health: The Rise of Metabolic Psychia

If a person's waist circumference is more than half their height, there is roughly a 90% chance they have insulin resistance.

"if your waist circumference is more than half your height, there's about a 90% chance that you've got insulin resistance." (said at 0:50:37)

A waist circumference greater than half of height (waist-to-height ratio ≥ 0.5) is a well-established anthropometric screening threshold for central adiposity and insulin resistance. However, claiming that exceeding this cutoff gives 'about a 90% chance' of having insulin resistance overstates its diagnostic accuracy. ROC curve analyses evaluate waist-to-height ratio with an area under the curve (AUC) around 0.71 to 0.74, with optimal cut-off values around 0.50-0.53. In general populations, a screening threshold of 0.5 yields moderate diagnostic performance rather than a ~90% positive predictive value (post-test probability), meaning that while it is an effective screening tool, having a ratio over 0.5 does not equate to a 90% certainty of having insulin resistance.

0:52:43overstatedmoderateRevolutionizing Mental Health: The Rise of Metabolic Psychia

A fasting triglyceride level over 100 mg/dL (or over 1.1 mmol/L) indicates excess dietary carbohydrate consumption relative to one's metabolic capacity.

"If the triglycerides are over 100 milligrams per deciliter, or over 1.1 millimoles if you're outside the United States, then that's a clue that you're eating too much carbohydrate for your personal metabolism." (said at 0:52:43)

While carbohydrate restriction lowers circulating triglycerides and high intakes of refined carbohydrates or sugars can stimulate hepatic de novo lipogenesis and elevate triglycerides—especially in individuals with insulin resistance—fasting triglycerides exceeding 100 mg/dL (1.1 mmol/L) do not uniquely or definitively indicate excess dietary carbohydrate intake. Standard clinical guidelines define normal fasting triglycerides as <150 mg/dL (<1.7 mmol/L). Furthermore, elevated triglycerides are multifactorial, commonly driven by total caloric surplus, adiposity, alcohol intake, genetic variations in lipid clearance, hypothyroidism, renal disease, and various medications, rather than solely dietary carbohydrate exceeding metabolic capacity.

0:53:44unverifiedvery lowRevolutionizing Mental Health: The Rise of Metabolic Psychia

Fasting glucose, fasting insulin, and fasting triglycerides can be lowered within days to weeks with dietary interventions.

"You can bring your fasting glucose down, you can bring your fasting insulin down, you can bring your fasting triglycerides down within a matter of days to weeks if you have the right information." (said at 0:53:44)

No published record matching the claim that fasting glucose, fasting insulin, and fasting triglycerides can be lowered within days to weeks with dietary interventions was located; this does not prove the claim false.

0:55:03supportedhighRevolutionizing Mental Health: The Rise of Metabolic Psychia

Hemoglobin A1C reflects an individual's average blood sugar levels over the preceding three months.

"The hemoglobin A1C is a reflection of your average blood sugar over the past three months." (said at 0:55:03)

Hemoglobin A1c (HbA1c) is a well-established clinical biomarker that reflects an individual's average blood glucose exposure over the preceding 2 to 3 months (approximately 120 days, corresponding to the average lifespan of human red blood cells).

0:55:20supportedmoderateRevolutionizing Mental Health: The Rise of Metabolic Psychia

Postprandial glucose spikes are among the earliest indicators of metabolic dysfunction before fasting glucose rises.

"And so if you're getting these peaks after meals, that's really one of the first clues to metabolic dysfunction or to the clue that you're eating the wrong way. It'll all come back down to normal by the next morning until you've got type 2 diabetes." (said at 0:55:20)

Established metabolic research shows that postprandial hyperglycemia (impaired glucose tolerance) is one of the earliest measurable dysfunctions in the progression toward type 2 diabetes, typically developing years before fasting plasma glucose becomes abnormal. In impaired glucose tolerance, loss of early-phase insulin secretion causes elevated postprandial glucose excursions while basal hepatic glucose output and fasting plasma glucose remain normal or near normal.

Fact-checked episodes

Publications